JPWO2022136673A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022136673A5 JPWO2022136673A5 JP2023533634A JP2023533634A JPWO2022136673A5 JP WO2022136673 A5 JPWO2022136673 A5 JP WO2022136673A5 JP 2023533634 A JP2023533634 A JP 2023533634A JP 2023533634 A JP2023533634 A JP 2023533634A JP WO2022136673 A5 JPWO2022136673 A5 JP WO2022136673A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- molecule
- double
- stranded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000039446 nucleic acids Human genes 0.000 claims 31
- 108020004707 nucleic acids Proteins 0.000 claims 31
- 150000007523 nucleic acids Chemical class 0.000 claims 31
- 229920002477 rna polymer Polymers 0.000 claims 16
- 230000002401 inhibitory effect Effects 0.000 claims 15
- 239000002773 nucleotide Substances 0.000 claims 15
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 108020004414 DNA Proteins 0.000 claims 9
- 102000053602 DNA Human genes 0.000 claims 9
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 7
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000000692 anti-sense effect Effects 0.000 claims 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 3
- 108091081021 Sense strand Proteins 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000000813 microbial effect Effects 0.000 claims 3
- ZTWTYVWXUKTLCP-UHFFFAOYSA-L ethenyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)C=C ZTWTYVWXUKTLCP-UHFFFAOYSA-L 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 101710095342 Apolipoprotein B Proteins 0.000 claims 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 102000016918 Complement C3 Human genes 0.000 claims 1
- 108010028780 Complement C3 Proteins 0.000 claims 1
- 101710172072 Kexin Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2020534.0A GB202020534D0 (en) | 2020-12-23 | 2020-12-23 | Conjugate |
| GB2020534.0 | 2020-12-23 | ||
| PCT/EP2021/087570 WO2022136673A1 (en) | 2020-12-23 | 2021-12-23 | Conjugate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024500036A JP2024500036A (ja) | 2024-01-04 |
| JPWO2022136673A5 true JPWO2022136673A5 (https=) | 2024-12-26 |
| JP2024500036A5 JP2024500036A5 (https=) | 2024-12-26 |
Family
ID=74221032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533634A Pending JP2024500036A (ja) | 2020-12-23 | 2021-12-23 | 抱合体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240352463A1 (https=) |
| EP (1) | EP4244357A1 (https=) |
| JP (1) | JP2024500036A (https=) |
| GB (2) | GB202020534D0 (https=) |
| WO (1) | WO2022136673A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120265773A (zh) * | 2022-10-14 | 2025-07-04 | 美国圣因生物股份有限公司 | 靶向c3的小干扰rna及其用途 |
| WO2024169908A1 (zh) * | 2023-02-17 | 2024-08-22 | 苏州时安生物技术有限公司 | 一种调节补体C5表达的siRNA、其缀合物和药物组合物及用途 |
| WO2024187102A2 (en) * | 2023-03-09 | 2024-09-12 | Leal Therapeutics, Inc. | Compositions and methods for modulating c3 |
| EP4680740A1 (en) * | 2023-03-14 | 2026-01-21 | Argonaute Rna Limited | Conjugate comprising a double stranded rna molecule linked to a single stranded dna molecule |
| GB2629617B (en) * | 2023-05-04 | 2025-05-14 | Argonaute Rna Ltd | Dual Silencing |
| WO2024228030A2 (en) * | 2023-05-04 | 2024-11-07 | Argonaute RNA Limited | Dual silencing |
| AU2024312039A1 (en) * | 2023-06-21 | 2026-01-22 | Changzhou Hansoh Pharmaceutical Co., Ltd. | Sirna, conjugate which contain sirna, pharmaceutical composition and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2500224C (en) | 2002-09-25 | 2015-04-28 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| EP1863912A2 (en) | 2005-03-08 | 2007-12-12 | Qiagen GmbH | Modified short interfering rna |
| US8067572B2 (en) * | 2005-05-25 | 2011-11-29 | The University Of York | Hybrid interfering RNA |
| EP2845607A1 (en) | 2013-09-09 | 2015-03-11 | University of Vienna | Antisense oligonucleotides with improved pharmacokinetic properties |
| JP7105065B2 (ja) * | 2014-12-15 | 2022-07-22 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | リガンド修飾二本鎖核酸 |
| EP4365291A3 (en) * | 2015-06-12 | 2024-08-14 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| JPWO2018164186A1 (ja) * | 2017-03-09 | 2020-01-09 | 協和キリン株式会社 | Ｍａｓｐ２の発現を抑制する核酸 |
| WO2018185252A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Nucleic acid conjugates |
| CA3119234A1 (en) * | 2018-11-23 | 2020-05-28 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of c3 in a cell |
| US20230027604A1 (en) * | 2019-07-02 | 2023-01-26 | Argonaute RNA Limited | Apolipoprotein b antagonist |
| US20230183694A1 (en) * | 2020-03-16 | 2023-06-15 | Argonaute RNA Limited | Antagonist of pcsk9 |
-
2020
- 2020-12-23 GB GBGB2020534.0A patent/GB202020534D0/en not_active Ceased
-
2021
- 2021-12-23 WO PCT/EP2021/087570 patent/WO2022136673A1/en not_active Ceased
- 2021-12-23 EP EP21845035.1A patent/EP4244357A1/en not_active Withdrawn
- 2021-12-23 GB GB2118938.6A patent/GB2604987A/en not_active Withdrawn
- 2021-12-23 US US18/268,769 patent/US20240352463A1/en active Pending
- 2021-12-23 JP JP2023533634A patent/JP2024500036A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Buchardt et al. | Peptide nucleic acids and their potential applications in biotechnology | |
| JP2020188756A5 (https=) | ||
| AU684748B2 (en) | Foldback triplex-forming oligonucleotides | |
| US6140492A (en) | Antisense transcript expressed in B lymphocytes and synthetic oligonucleotides useful to inhibit the activity thereof | |
| JP2019214587A5 (https=) | ||
| Gee et al. | Assessment of high-affinity hybridization, RNase H cleavage, and covalent linkage in translation arrest by antisense oligonucleotides | |
| EP2407558A1 (en) | Methods for the detection of a single- or double-stranded nucleic acid molecule | |
| CA2457528A1 (en) | Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina) | |
| JP2009514877A5 (https=) | ||
| JP2005517427A5 (https=) | ||
| PT1527176E (pt) | Novas formas de muléculas de arn de interferência | |
| CN115516092A (zh) | 血管生成素样3(ANGPTL3)的siRNA及其用途 | |
| JP2010532163A5 (https=) | ||
| WO2003042385A2 (en) | Gene silencing using sense dna and antisense rna hybrid constructs | |
| US6087484A (en) | Enhancement of ribozyme catalytic activity by A 2'-O-substituted facilitator oligonucleotide | |
| EP2062586A3 (en) | Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors | |
| JPWO2022136673A5 (https=) | ||
| JP2003517283A (ja) | プライマーペアの増幅及び配列決定並びにそれらの使用 | |
| JPWO2021195307A5 (https=) | ||
| JPWO2023041508A5 (https=) | ||
| JP2003504018A5 (https=) | ||
| WO1996035706A1 (en) | Pyrimidine targeting hairpin triplex-forming oligonucleotides | |
| JPWO2021087036A5 (https=) | ||
| JP2002526072A (ja) | 遺伝子発現の調節のためのヘアピンハイブリダイザー分子 | |
| JPWO2023044370A5 (https=) |